WELLELL (4106) Monthly Revenue

Market: TWSE-listed · Industry: Biotech & Medical · 雃博

WELLELL (4106) reported revenue of NT$198.2 million for Oct 2026, -5.1% year on year and -12.7% from the previous month. Revenue for Jan–Oct 2026 was NT$2.13 billion (+7.3% year on year).

In Oct 2026, it ranked No. 42 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$205.8 million24/10Nov 2024 NT$193.8 millionDec 2024 NT$214 millionJan 2025 NT$191.6 millionFeb 2025 NT$170.2 million25/02Mar 2025 NT$194.4 millionApr 2025 NT$188.8 millionMay 2025 NT$206 millionJun 2025 NT$209.7 million25/06Jul 2025 NT$218.1 millionAug 2025 NT$202.5 millionSep 2025 NT$198.5 millionOct 2025 NT$208.9 million25/10Nov 2025 NT$197.5 millionDec 2025 NT$218 millionJan 2026 NT$187 millionFeb 2026 NT$188.3 million26/02Mar 2026 NT$207.9 millionApr 2026 NT$221.7 millionMay 2026 NT$186.4 millionJun 2026 NT$265.8 million26/06Jul 2026 NT$220.7 millionAug 2026 NT$230.9 millionSep 2026 NT$227.1 millionOct 2026 NT$198.2 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$198.2 million-5.1%-12.7%
Sep 2026NT$227.1 million+14.4%-1.7%
Aug 2026NT$230.9 million+14.0%+4.6%
Jul 2026NT$220.7 million+1.2%-17.0%
Jun 2026NT$265.8 million+26.8%+42.6%
May 2026NT$186.4 million-9.5%-15.9%
Apr 2026NT$221.7 million+17.5%+6.6%
Mar 2026NT$207.9 million+7.0%+10.4%
Feb 2026NT$188.3 million+10.6%+0.7%
Jan 2026NT$187 million-2.4%-14.2%
Dec 2025NT$218 million+1.9%+10.4%
Nov 2025NT$197.5 million+1.9%-5.4%
Oct 2025NT$208.9 million+1.5%+5.2%
Sep 2025NT$198.5 million+18.0%-2.0%
Aug 2025NT$202.5 million+12.1%-7.2%
Jul 2025NT$218.1 million+13.0%+4.0%
Jun 2025NT$209.7 million+10.8%+1.8%
May 2025NT$206 million+7.2%+9.1%
Apr 2025NT$188.8 million-7.0%-2.9%
Mar 2025NT$194.4 million-6.6%+14.2%
Feb 2025NT$170.2 million-6.7%-11.2%
Jan 2025NT$191.6 million-25.2%-10.5%
Dec 2024NT$214 million-7.1%+10.4%
Nov 2024NT$193.8 million-16.7%-5.9%
Oct 2024NT$205.8 million-4.6%+22.4%

Jan–Oct 2026 cumulative: NT$2.13 billion (+7.3% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: WELLELL vs PEC / WELLELL vs Lotus Pharm / WELLELL vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16